{"id":"W2949744877","doi":"10.1002/hon.211_2631","title":"PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Mycosis fungoides; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Brentuximab vedotin; Oncology; Cutaneous T-cell lymphoma; Clinical endpoint; Phases of clinical research; Gastroenterology; T cell; Chemotherapy; Clinical trial; Immunology; Hodgkin lymphoma; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001042532,0.0008884951,0.001133213,0.0003203768,0.000328563,0.0005810024,0.0005826195,0.0005648693,0.00202081],"category_scores_gemma":[0.0006357191,0.0002424454,0.0008943839,0.0003202962,0.0004663324,0.0004176091,0.0002967683,0.001909664,0.0005616294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005380397,"about_ca_system_score_gemma":0.0004920428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001096104,"about_ca_topic_score_gemma":0.002363781,"domain_scores_codex":[0.9996026,0.0002187693,0.0000295778,0.00003735452,0.00004245398,0.00006930577],"domain_scores_gemma":[0.9995393,0.0001202641,0.00007362468,0.00005832017,0.00003753788,0.0001710183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1752659,0.05360978,0.01341482,0.002125875,0.001678193,0.004350934,0.001534061,0.008652374,0.4540001,0.0004074622,0.007537955,0.2774224],"study_design_scores_gemma":[0.07321219,0.7930914,0.05682863,0.00008508221,0.001100161,0.004721195,0.0002994964,0.003796587,0.0557038,0.0002919614,0.01081044,0.00005897374],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936832,0.002385477,0.0006386121,0.0002714008,0.00003614159,0.0005121594,0.0006374146,0.00008435434,0.001751312],"genre_scores_gemma":[0.9944023,0.001580986,0.0005765263,0.0003101818,0.00005558707,0.0002955832,0.00138628,0.00002154791,0.001370958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00202081,"threshold_uncertainty_score":0.006760299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.017398915298579,"score_gpt":0.2915257158867403,"score_spread":0.2741268005881612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}